Biobanks Market Size Worth USD 74.54 Billion By 2025

The global biobanks market size is expected to reach USD 74.54 billion by 2025 at a 4.5% CAGR over the forecast period, according to a new report by Grand View Research, Inc. Growing need for sample collection to support and facilitate clinical trials for novel therapies, which are developed for treatment of chronic conditions, is anticipated to boost the market.

Different biospecimens stored at biobanks are witnessing significant demand owing to advancements in cell-based research activities. Rising demand from different end users has led to establishment of a substantial number of population-based and disease-based banks in recent years. Population-based banks are established to support precision medicine research initiatives, whereas disease-specific biobanks provide resources to research communities to enable a better understanding of disease etiology.

Furthermore, there has been a rapid increase in number of biobanks over the recent past, which can be attributed to perpetual developments in cell-based therapies, such as advent of stem cells and regenerative medicine. Thus, competition among biobanks is observed within for-profit biostorage entities that provide open access to researchers and hospitals. Increase in efforts undertaken by life science industries for collaboration with biobanks to support life science research programs is expected to further boost the market.

In addition, regional biobank networks are being established to enhance accessibility to biospecimens and promote international sharing of these samples. Few examples of such networks are BBMIR-ERIC, Asian Network of Research Resource Centers, and Asian Consortium for the Conservation and Sustainable Use of Microbial Resources.

Increase in number of clinical trials for new drug candidates has spurred demand for biobanking services. Major challenges in biobanking operations include sustainability, limited access, and information sharing. However, technology advancements aid in overcoming these hurdles. Owing to introduction of novel applications of stored cells and biospecimens in drug development, leading economies such as U.S. and U.K. are revising their regulatory policies and guidelines pertaining to biobanking operations.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/biobanks-industry

Further key findings from the report suggest:

• Biobanking equipment held the dominant share by product in 2017. High cost of equipment, coupled with rapid increase in number of biobanks, is attributive to its leading revenue share
• The LIMS segment is projected to witness lucrative growth over the forecast period owing to rise in efforts undertaken for improvement of sample quality to suit international standards
• North America dominated the global market in 2017 owing to high demand for biosamples. This increase in demand is attributive to rapid advancement of genomics, bioinformatics, and translational research
• Asia Pacific is projected to exhibit the fastest growth due to rapid progress of Asian countries in healthcare, drug discovery, and scientific research
• Some of the major companies offering biobanking products are QIAGEN; Thermo Fisher Scientific Inc.; Agilent Technologies, Inc.; and Merck KGaA. VMR International, Charles River, Lonza, Biovault, Thermo Fisher Scientific (Fisher BioServices), and Virgin Health Bank are among prominent companies engaged in offering biobanking services.

Medical Device Cleaning Market Size Worth USD 15.9 Billion By 2025

The global medical device cleaning market size is expected to reach USD 15.9 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 6.3% during the forecast period. High adoption of advanced methods and materials to prevent infections in hospitals and increase in the number of hospitals & other healthcare facilities, including clinics, are expected to boost market growth.

Other key factors expected to enhance the market growth include strict regulations and guidelines to reduce incidences of hospital-acquired infections coupled with introduction of novel methods & materials for cleaning, disinfecting, and sterilizing medical devices. Increase in the number of contractual service providers for reprocessing and manufacturers of materials required in these processes is also anticipated to propel the market.

Guidelines and regulation by U.S. FDA play an important role in determining market dynamics. They profile various materials along with their effects in cleaning & disinfecting medical devices and risks associated with them. In addition, they regulate standards of tests for disinfection. Most developing countries follow similar guidelines, especially those in the Asia Pacific region, where medical tourism is booming and primary customers include patients from developed countries.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/medical-device-cleaning-market

Further key findings from the report suggest:

• Semi-critical devices accounted for the largest share in 2017 and is expected to dominate throughout forecast period. High usage and need for repeated sterilization between patients are among the key factors anticipated to drive the growth of the segment
• The disinfection segment dominated the market in 2017 and is expected to maintain the largest share throughout the forecast period. Introduction of novel and advanced disinfectants is likely to supplement the growth of the segment
• Sterilization is expected to exhibit the fastest growth during the forecast period. Adoption of advanced sterilization procedures in hospitals is expected to boost the growth of the segment
• Asia Pacific is anticipated to exhibit the highest CAGR during the forecast period. High demand for advanced medical device reprocessing equipment and materials owing to increasing medical tourism is one of the primary growth drivers in the region.

Metagenomics Market Size Worth USD 1.40 Billion By 2025

The global metagenomics market size is expected to reach USD 1.40 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 16.6% during the forecast period. Rise in demand for microbial screening in food and chemical industries for commercial applications, coupled with rapid developments in bioinformatics and biotechnology tools, is anticipated to accelerate market growth in the coming years.

Key market participants are striving to capitalize potential avenues in the market by addressing challenges faced by research entities pertaining to data assembly, identification, and verification of rare metagenomes. Furthermore, companies operating in the molecular diagnostics and genomics arena are a playing crucial role in this market by partnering with metagenomics companies for development of novel tests for disease diagnosis.

For instance, in September 2017, IDbyDNA, Inc. and ARUP Laboratories co-developed Explify Respiratory-a metagenomic NGS test for screening of respiratory infections. The anticipated launch of many such novel tests is projected to boost the market during the forecast period.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/metagenomics-market

Further key findings from the report suggest:

• Kits and reagents formed the largest segment by product in 2017 owing to frequent usage at various steps in microbial genomic studies
• Surplus growth in genomics database with respect to types and numbers has led to rising demand for better data analysis solutions. As a result, the sequencing and data analytics services segment is expected to emerge as a lucrative source of revenue generation during the forecast period
• Function driven technology held the major revenue share in 2017. Development of new screening procedures that facilitate rapid screening of large clone libraries has enabledfunctional detection of novel enzymes from metagenomes
• Advancements in genetic tools have broadened the application scope of metagenomics to include targeting microbes responsible for inducing various cancer forms. This, in turn, is driving the application of metagenomic analysis in human health
• North America dominated the market in 2017. Strong presence of key NGS leaders like Illumina and a substantial number of ongoing genomics-related studies in U.S. are major factors contributing to its large share
• Some of the key competitors in the market are Illumina, Inc.; Promega Corporation; Novogene Corporation; Oxford Gene Technology, Inc.; Thermo Fisher Scientific, Inc.; TAKARA BIO INC.; Danaher; QIAGEN; and ELITechGroup
• Acquisition of small players with a strong product portfolio is a prominently adopted strategy by dominant players. For instance, in August 2016, PerkinElmer acquired Bioo Scientific Corporation-provider of 16S & 18S library preparation kits for metagenome studies
• Competitors are also involved in collaborations with bioinformatics companies for co-development of novel platforms for metagenomics analysis.

Trauma Devices Market Size Worth USD 11.2 Billion By 2025

The global trauma devices market size is expected to reach USD 11.2 billion in 2025, according to a new report by Grand View Research, Inc., registering a 6.1% CAGR during the forecast period. Increasing incidence of severe fractures and rising expenditure on research and development of trauma devices are among key factors likely to drive the market during the forecast period. Medical devices used for fixation of small bones and joints are categorized under orthopedic trauma.

The market for trauma devices is likely to witness high growth in the coming years due to rising geriatric population and surge in number of road accidents. The market is driven by technological advancements, with key players introducing array of products through extensive research capabilities and expanding their segment portfolio through partnerships with other players.

For instance, in July 2017, Cardinal Health acquired the patient recovery business from Medtronic for USD 6.1 billion. The acquisition helped expand Cardinal Health’s portfolio by adding 23 product categories, including segment leader brands such as Kendall, Curity, Kangaroo, Dover, and Argyle.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/trauma-devices-market

Further key findings from the report suggest:

• Rising number of road accidents and increase in expenditure on research and development is expected to drive the trauma devices market from 2018 to 2025
• Osteoporotic fractures affect around 8.9 million people every year, mainly menopausal women, and causes osteoporotic fracture in more than 30.0% women over the age of 50
• Around 40.0% of trauma injuries occur due to falls and motor vehicle accidents. Elderly population as well as children below the age of 7 are more prone to falls. Motor vehicle accidents account for over 28% of trauma injuries
• Internal fixators dominated the market by type in 2017; however, external fixators are anticipated to grow at the fastest rate over the forecast period
• Key industry contributors include Depuy Synthes, Stryker; Zimmer Biomet, Smith & Nephew, Wright Medical Group N.V., Advanced Orthopaedic Solutions, Integra LifeSciences, Acumed, Bioretec Ltd., and Cardinal Health.

Eye Examination Equipment Market Size Worth USD 8.8 Billion By 2025

The global eye examination equipment market size is expected to reach USD 8.8 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 6.2% during the forecast period. Increasing prevalence of eye-related disorders is anticipated to drive the demand for advanced ophthalmic treatment procedures over the forecast period.

Growing global geriatric population is another factor propelling the optometry/eye examination equipment market. According to U.S. Census Bureau published on June 2017, the total population aged 65 and older in the U.S. increased to 49.2 million in 2016, accounting for 15.2% of the total population, from 35 million in 2000, which represented only 12.0% of the total population. Mounting cases of age-related disorders including glaucoma, cataracts, and age-related macular degeneration (AMD) are likely to stoke the growth of the market.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/optometry-eye-examination-equipment-market

Further key findings from the report suggest:

• Growing prevalence of eye diseases and influx of technologically advanced ophthalmic devices are anticipated to boost the growth of the optometry/eye examination equipment market over the forecast period
• Ophthalmic ultrasound imaging systems are expected to exhibit the fastest growth over the coming years, owing to rising penetration of  B-Scan ultrasound
• Hospitals accounted for the largest revenue share in the market in 2017, owing to rising ophthalmic surgical procedures in hospitals
• North America held the dominant share in the optometry/eye examination equipment market in 2017, due to presence of well-established healthcare setting and treatment facility, surging demand for technologically advanced healthcare products, and favorable reimbursement facilities.
• The market in Asia Pacific, especially Japan and India, are estimated to witness remarkable growth during the forecast period due to increasing investments in the healthcare sector. In Feb 2017, the Japan government invested USD 500 million to build a new eye hospital in order to fulfil the vision 2020 approach by WHO.
• Some of the key companies present in the market are Carl Zeiss Meditec AG; Bausch & Lomb Inc.; Johnson & Johnson Vision Care Inc.; Novartis AG; NIDEK CO.; LTD; and Canon

Cannula Market Size Worth USD 212.0 Million by 2026

The global cannula market size is expected to reach USD 212.0 million by 2026 at a 7.5% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Increasing demand for minimally invasive surgeries, growing number of surgeries among geriatric population, advancement in healthcare facilities, and rising government support and R&D investments are anticipated to drive the cannula market.

The market is also driven by increasing prevalence of lifestyle-related diseases such as obesity. Market players are continuously involved in introducing new technologies to cater to this trend. PROTEK Duo cannula, new injection molding technology and single-use cannulas for surgery, is one such example.

Key players operating in the market are using different strategies such as new product development, investment in R&D, acquisitions, partnerships, joint ventures, and agreements to increase their foothold in this market.

The cannula market in developed economies, such as U.S., Germany, France, and Australia, is comparatively mature owing to presence of well-established market players in these countries and high demand for such products.

On the other hand, developing countries in Asia and Latin America currently have a moderate adoption rate of these products, thus presenting more scope for market expansion. Growth of medical tourism and rising patient awareness in these countries are anticipated to propel the market. Manufacturing companies investing in these rapidly developing markets are expected to grow at a lucrative rate, provided pricing and distribution activities are undertaken efficiently.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/cannulas-market

Further key findings from the report suggest:

• Dermatology cannulas are projected to witness a CAGR of more than 8.0% over the forecast period. This can be attributed to massive patient pool and increasing number of surgeries, especially in U.S.
• Asia is estimated to witness the highest growth rate in the global market, due to increase in penetration of market players, large geriatric patient pool, and increasing healthcare expenditure
• Some of the key companies in the market are Medtronic, Edward Lifesciences, LivaNova, Terumo Corporation, Teleflex, Smiths Medical, Boston Scientific Corporation, CONMED, and Smith & Nephew.

Mouth Ulcers Treatment Market Size Worth USD 1.32 Billion By 2026

The global mouth ulcers treatment market size is projected to reach USD 1.32 billion by 2026, according to a new report by Grand View Research, Inc., progressing at a CAGR of 3.8% during the forecast period. Increasing geriatric population and rising awareness towards oral hygiene are among the key trends stimulating market growth.

Growing global geriatric population is poised to trigger the number of cases of mouth ulcers. As per the findings of the United Nations Organization (UNO), population base of age 60 years or older across the globe was 962.0 million in 2017, which was more than twice as large as in 1980, when the population was 382.0 million. With upswing in the demand for denture fittings in this population, rise in the incidences of improper fittings and deficiency of vitamin B & folic acid is anticipated. Such incidents can lead to mouth ulcers.

Newly fitted dentures takes some time to adjust. During the procedure, inner area of the mouth remains moist for a certain period. Such conditions favor fungal infection leading to ulcer. Older population often suffer from such conditions, due to which they are prone to oral problems. In addition, deficiency of vitamins is a common phenomenon observed among geriatric population, which also increases the probability of suffering from mouth ulcer.

Rising awareness regarding oral hygiene in developing countries is also estimated to drive the market over the forecast period. Campaigns on oral hygiene in rural areas of developing countries are working in favor of the market. For instance, every year, Colgate-Palmolive Company conducts an oral health month in rural areas of India in order to impart awareness regarding oral hygiene. Such initiatives are expected to encourage people to take up necessary treatments. Furthermore, rise in tobacco usage in countries such as U.K. and Mexico is projected to boost the rate of mouth ulcers, thereby benefitting the growth of the market.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/mouth-ulcers-treatment-market

Further key findings from the report suggest:

• Analgesics and Corticosteroids are poised to exhibit the highest CAGR during the forecast period. These are the most prescribed drugs by doctors and are easily available
• By 2026, Asia Pacific is likely to dominate the mouth ulcer treatment market with a share of around 63.0%. Increasing awareness pertaining to oral hygiene and treatment and rising prevalence of aphthous ulcers are likely to supplement the growth of the market
• Some of the key companies present in the market are Blistix Inc., Church & Dwight Co., Inc., 3M, Colgate-Palmolive Company, Pfizer, Bristol-Myers Squibb (BMS), and others are expected to dominate the market over the forecast period.

Trocars Market Size Worth USD 991.1 Million By 2026

The global trocars market size is estimated to reach USD 991.1 million by 2026, according to a new report by Grand View Research, Inc., progressing at a CAGR of 4.3% during the forecast period. Rising geriatric population, increasing reliance on laparoscopic surgeries, and favorable reimbursement policies in developed countries are some of the primary growth stimulants for the market.

Favorable reimbursement policies by governments and key players for surgical devices and instruments are projected to boost the growth of the market over the forecast period. Key players are providing favorable reimbursement policies in order to promote minimally invasive surgeries, laparoscopic surgeries, and bariatric surgeries. For instance, Ethicon (subsidiary of Johnson & Johnson) conducts Reimbursement Support Program to help healthcare providers with reimbursement related to laparoscopic surgeries and minimally invasive surgeries. These initiatives are most likely to help healthcare providers to take up these procedures instead of traditional ones. Thus, these factors are likely to drive the market over the forecast period.

In addition, the volume of surgeries has increased manifolds due to increasing geriatric population worldwide. Geriatric population are prone to various diseases, which require various surgical interventions for treatment. According to estimates published by WHO, the global elderly population is likely to increase from 841.0 million in 2014 to more than 2.0 billion by 2050.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/trocars-market

Further key findings from the report suggest:

• The global disposable trocars market is expected to dominate the market in 2017. Disposable trocars deliver high quality medical output and the chance of post-operative infection is low.
• Optical trocars are anticipated to be the fastest growing segment with a CAGR of over 4.5% owing to increasing demand for technologically advanced devices for surgeries
• Gynaecological surgery represented the largest share in 2017, with a valuation of USD 174.64 million, owing to increasing prevalence of gynaecological disorders across the globe.
• North America dominated the market in 2017 and accounted for approximately half of market revenue. Rising number of surgeries, advancements in healthcare infrastructure, and increasing demand for technologically advanced surgical procedures are contributing to the growth of the region
• Asia Pacific is poised to witness the highest growth in the market due to high population, rising geriatric population, and expanding base of patients with unmet needs
• Some of the key companies present in the market are CONMED Corporation; The Cooper Companies Inc.; Teleflex Incorporated; GENICON, Inc.; Medtronic; B.Braun Medical Inc.; and Johnson & Johnson.              

Psoriasis Drugs Market Size Worth USD 21.11 Billion by 2022

The global psoriasis drugs market size is expected to be valued at USD 21.11 billion by 2022, as per a new report by Grand View Research, Inc., experiencing a CAGR of 9.4% during the forecast period. Rising disease awareness, increasing number of reimbursement strategies for biologics, and advanced diagnostic and technological tools are likely to increase the adoption of psoriasis therapeutics.

Additionally, expanding base of patients suffering from psoriasis is anticipated to fuel growth prospects. The exact causative factors for psoriasis are undetermined; however, certain genetic and environmental factors may trigger the disease onset. Most available treatments aim to decelerate disease progression by stopping hyperproliferation of keratinocyte.

Psoriasis can be classified into five types: plaque, guttate, inverse, pustular, and erythrodermic. The types vary in terms of site of disease and characterization of lesions. Erythrodermic psoriasis is the rarest and plaque psoriasis is the most prevalent type affecting patients all over the world.

Incidence rate of psoriasis has witnessed a gradual rise over the years across various geographical locations. This increase can be attributed to genetic and environmental triggers as well as lifestyle changes. Rise in prevalence rates could also be associated with declining response or developing resistance to therapies for disease control.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/psoriasis-drugs-market

Further key findings from the report suggest:

• Tumor Necrosis Factor-inhibitors dominated the market in 2016 owing to its higher usage by healthcare practitioners and easy availability
• TNF-inhibitors are likely to lose market shares over the forecast period due to increasing preference for IL-inhibitor therapy to conventional TNF-inhibitors
• Interleukin-inhibitors is expected to register a lucrative CAGR of over 21.0% during the forecast period owing to improved safety and efficacy profiles of Interleukin-inhibiting drugs
• The U.S is the dominant region in the psoriasis market in terms of revenue in 2016 due to increasing number of patients seeking treatment and presence of well-established healthcare services
• Japan is expected to be the fastest growing region during the same period due to growing awareness about the disease among the populace
• Some of the key players in this industry are AbbVie Inc.; Amgen Inc.; Johnson & Johnson; Novartis AG; Eli Lilly & Company; AstraZeneca; Celgene Corporation; UCB; and Merck.

Sustained Release Excipients Market Size Worth USD 1.6 Billion By 2026

The global sustained release excipients market size is expected to reach USD 1.6 billion by 2026 at a 7.1% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Increasing focus on novel drug delivery R&D and rising adoption of extended release formulations for treatment of chronic diseases are major factors driving the market.

Use of sustained release drug formulations provides patients relief from these symptoms and helps maintain desired therapeutic drug levels in the body. In comparison to conventional drugs, sustained drug release technologies provide a wide range of benefits. Reduced dosage frequency, improved patient compliance, maintenance of constant level of drug in blood plasma, lower instances of toxicity due to overdose, and higher cost-effectiveness in the long run are some of the major advantages of using this technology.

Global rise in incidence of chronic and infectious diseases has also resulted in antibiotic resistance, which negatively affects the market for conventional dosage forms. Thus, alternative methods to manage and treat these diseases are being implemented. Use of sustained release formulations has been widely accepted among physicians in order to combat antibiotic resistance. Since these formulations create desired therapeutic drug levels in blood plasma and reduce dosage frequency, they are the preferred choice of formulation among physicians, which increases their demand.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/sustained-release-excipients-market

Further key findings from the report suggest:

• Polymers formed the largest revenue grossing segment by product type in 2017 and is anticipated to grow at a lucrative rate during the forecast period. This is due to its high adoption in sustained release formulations as they provide greater strength and improved shelf-life
• In terms of route of administration, the oral segment held the dominant share in 2017 and is projected to witness steady growth to retain its lead throughout the forecast period
• Transdermal technology is expected to exhibit the highest CAGR during the forecast period owing to its escalating usage. It minimizes various limitations associated with oral and parenteral route of administrations
• North America dominated the overall market in 2017 due to well-developed research infrastructure and presence of leading pharmaceutical and biopharmaceutical companies
• Asia Pacific is spearheading revenue growth, with Japan, China, and India at the forefront
• Some of the key companies in the market are Coating Place, Inc.; Depomed, Inc.; Corium International, Inc.; Capsugel; Aradigm Corporation; Orbis Biosciences, Inc.; and Alkermes plc.

Migraine Drugs Market Size Worth USD 7.8 Billion by 2025

The global migraine drugs market size is expected to be valued at USD 7.8 billion by 2025, as per a new report by Grand View Research, Inc., exhibiting an 18.0% CAGR during the forecast period. The market is largely driven by factors such as rise in disease prevalence, development of novel therapies, lifestyle changes, and hormonal medications.

Migraine is a debilitating neurological disease characterized by recurrent attacks of severe throbbing head pain that can last for more than three days. Migraine pain may get worse on movement, preventing the patient from carrying out normal, day-to-day activities. In about one-third of attacks, both sides of the head, face, or neck are affected.

Over the past five years, the global migraine drugs market has been relatively stagnant, with the market mainly dominated by usage of generic triptans and other off-label drugs. Majority of the currently prescribed drugs for both acute and preventative treatment are associated with poor efficacy and an unfavorable side-effect profile.

Launch of Amgen/ Novartis’ CGRP mAb Aimovig and Teva Pharma’s Ajovy is the first step toward revolutionizing the treatment paradigm of migraine prevention. For drug manufacturers likely to enter the market by 2019, such as Eli Lilly, Alder BioPharma, and Biohaven Pharma, pricing will be a key differentiating factor as all CGRP-based therapies have a similar efficacy and safety profile.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/migraine-drugs-market

Further key findings from the report suggest:

• Germany leads the European market, driven by rising disease prevalence, novel drug launches, and increase in R&D activities
• The acute migraine treatment market will be supported by rapid uptake of novel drug classes such as CGRP receptor antagonists and ditans currently under active investigation in multiple Phase II/III trials
• Biohaven’s rimegepant is expected to face competition from Allergan's ubrogepant, which has shown superior efficacy in Phase III trials compared to rimegepant
• Eli Lilly’s Phase III 5-HT1F receptor agonist Lasmiditan is expected to be a novel first-line non triptan acute treatment option for patients in whom triptans are contradicted
• Approximately 20% of patients seeking preventive treatment for migraine do not respond to available generic medications. Several biologics and small molecules drugs are undergoing active development to target high unmet needs in the preventive treatment segment
• Drugs with novel targets in early-phase development include AOBiome Therapeutics’ AOB-203 (antibacterial), Winston Pharma’s Dolorac (histamine H1 receptor antagonists), NeuroAxons’ NXN-188 (combination of NOS inhibitor and a triptan), and Biohaven’s BHV-3500 (gepant). These novel agents are under evaluation for both episodic and chronic migraine in multiple Phase I/II trials.